Hydroxychloroquine retinopathy - implications of research advances for rheumatology care

被引：168

作者：

Jorge, April ^{[1
]}

Ung, Cindy ^{[2
]}

Young, Lucy H. ^{[2
]}

Melles, Ronald B. ^{[3
]}

Choi, Hyon K. ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA

[2] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA USA

[3] Kaiser Permanente Northern Calif, Dept Ophthalmol, Redwood City, CA USA

来源：

NATURE REVIEWS RHEUMATOLOGY | 2018年 / 14卷 / 12期

关键词：

SYSTEMIC-LUPUS-ERYTHEMATOSUS; OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; ANTIMALARIAL-DRUGS; TRIPLE THERAPY; CHLOROQUINE; TOXICITY; RISK; ARTHRITIS; RECOMMENDATIONS;

D O I：

10.1038/s41584-018-0111-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite advances in therapy for rheumatic diseases, hydroxychloroquine remains almost universally recommended for the treatment of systemic lupus erythematosus (SLE), and is often used in the management of other rheumatic diseases such as rheumatoid arthritis (RA). However, the major dose-limiting toxicity of hydroxychloroquine is retinopathy that can lead to loss of vision. New highly sensitive screening methods can identify early stages of retinopathy, and studies that include these modalities have indicated a substantially higher prevalence of hydroxychloroquine retinopathy than was previously recognized, resulting in revisions to ophthalmology guidelines and the recommendation of a low dose of hydroxychloroquine for many patients. However, the efficacy of low-dose hydroxychloroquine for treating SLE and other rheumatic diseases is unknown. Further studies are required to establish the effectiveness and retinal safety of the latest hydroxychloroquine treatment recommendations.

引用

页码：693 / 703

页数：11

共 91 条

[1] Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus:: Data from LUMINA, a multiethnic US cohort (LUMINA L) [J].

Alarcon, Graciela S. ;

McGwin, Gerald ;

Bertoli, Ana M. ;

Fessler, Barri J. ;

Calvo-Alen, Jaime ;

Bastian, Holly M. ;

Vila, Luis M. ;

Reveille, John D. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) :1168-1172

[2] Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis A Cost-Effectiveness Analysis [J].

Bansback, Nick ;

Phibbs, Ciaran S. ;

Sun, Huiying ;

O'Dell, James R. ;

Brophy, Mary ;

Keystone, Edward C. ;

Leatherman, Sarah ;

Mikuls, Ted R. ;

Anis, Aslam H. .

ANNALS OF INTERNAL MEDICINE, 2017, 167 (01) :8-+

[3] HYDROXYCHLOROQUINE SULFATE IN RHEUMATOID-ARTHRITIS - LONG-TERM RESPONSE RATE AND PREDICTIVE PARAMETERS [J].

BELL, CL .

AMERICAN JOURNAL OF MEDICINE, 1983, 75 (1A) :46-51

[4] OPHTHALMOLOGIC CONSIDERATIONS AND TESTING IN PATIENTS RECEIVING LONG-TERM ANTI-MALARIAL THERAPY [J].

BERNSTEIN, HN .

AMERICAN JOURNAL OF MEDICINE, 1983, 75 (1A) :25-34

[5] EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics [J].

Bertsias, G. ;

Ioannidis, J. P. A. ;

Boletis, J. ;

Bombardieri, S. ;

Cervera, R. ;

Dostal, C. ;

Font, J. ;

Gilboe, I. M. ;

Houssiau, F. ;

Huizinga, T. ;

Isenberg, D. ;

Kallenberg, C. G. M. ;

Khamashta, M. ;

Piette, J. C. ;

Schneider, M. ;

Smolen, J. ;

Sturfelt, G. ;

Tincani, A. ;

van Vollenhoven, R. ;

Gordon, C. ;

Boumpas, D. T. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :195-205

[6] Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis [J].

Bertsias, George K. ;

Tektonidou, Maria ;

Amoura, Zahir ;

Aringer, Martin ;

Bajema, Ingeborg ;

Berden, Jo H. M. ;

Boletis, John ;

Cervera, Ricard ;

Doerner, Thomas ;

Doria, Andrea ;

Ferrario, Franco ;

Floege, Juergen ;

Houssiau, Frederic A. ;

Ioannidis, John P. A. ;

Isenberg, David A. ;

Kallenberg, Cees G. M. ;

Lightstone, Liz ;

Marks, Stephen D. ;

Martini, Alberto ;

Moroni, Gabriela ;

Neumann, Irmgard ;

Praga, Manuel ;

Schneider, Matthias ;

Starra, Argyre ;

Tesar, Vladimir ;

Vasconcelos, Carlos ;

van Vollenhoven, Ronald F. ;

Zakharova, Helena ;

Haubitz, Marion ;

Gordon, Caroline ;

Jayne, David ;

Boumpas, Dimitrios T. .

ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (11) :1771-1782

[7] Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists An Electronic Medical Record-Based Study in an Integrated Health Care System [J].

Braslow, Rebekah A. ;

Shiloach, Mira ;

Macsai, Marian S. .

OPHTHALMOLOGY, 2017, 124 (05) :604-608

[8] Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines [J].

Browning, David J. ;

Lee, Chong .

CLINICAL OPHTHALMOLOGY, 2018, 12 :811-+

[9] The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both [J].

Browning, David J. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 166 :IX-XI

[10] Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy [J].

Browning, David J. ;

Lee, Chong .

CLINICAL OPHTHALMOLOGY, 2014, 8 :1389-1399

← 1 2 3 4 5 6 7 8 9 10 →